Lymphoma

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of Clinical Oncology.

The Leukemia & Lymphoma Society launched a national patient registry designed to improve understanding of how the novel coronavirus and COVID-19 vaccination affect people with blood cancer.

Patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel had similar response rates regardless of the type of center providing the chimeric antigen receptor T-cell therapy, according to study results.

COVID-19 infections in patients with hematologic malignancies tend to have a much worse prognosis, with mortality rates twice as high as those of patients without hematologic malignancies. These rates are currently up to 34% overall among adults and up to 47% among those aged older than 60 years. Underlying immunosuppression related to the malignancy itself and further potentiated by the therapy likely contributes to high mortality seen among these patients.

More than a year into the COVID-19 pandemic, new information emerges daily about the virus and its effects on various vulnerable populations.

In this video, Jing-Zhou Hou, MD, PhD, medical oncologist and hematologist, clinical instructor and co-chair of the hematological malignancies program at UPMC Hillman Cancer Center, discussed areas of unmet need in lymphoma care.

Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.

Sixty-five percent of patients with relapsed or refractory follicular lymphoma had an initial complete response to a single infusion of tisagenlecleucel, according to phase 2 study results presented at TCT Meetings Digital Experience.

An investigational chimeric antigen receptor T-cell therapy appeared safe and demonstrated antitumor activity among patients with relapsed or refractory B-cell malignancies, according to results presented at TCT Meetings Digital Experience.

Combining natural killer cells with high-dose chemotherapy and autologous stem cell transplant did not increase toxicity among patients with B-cell non-Hodgkin lymphoma, according to results presented at TCT Meetings Digital Experience.